Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission

ORION CORPORATION 
PRESS RELEASE
23 JUNE 2026 at 9:30 EEST
        
Orion Pharma’s ODM-212 Granted Orphan Designation for the Treatment of Malignant Mesothelioma by the European Commission